The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
email:
Melanie.Brewis@glasgow.ac.uk
Dept Resp medicine, Queen Elizabeth University hospital, Glasgow
Stubbs, H., Lua, S., Ingram, J., Jani, B. D. , Brewis, M., Church, C. and Johnson, M. (2023) Remote exercise testing in pulmonary hypertension (PHRET). Pulmonary Circulation, 13(4), e12325. (doi: 10.1002/pul2.12325) (PMID:38148951) (PMCID:PMC10749888)
Arogundade, F., Jani, B. , Church, C., Brewis, M., Johnson, M. and Stubbs, H. (2023) The MRC Dyspnoea Scale and mortality risk prediction in pulmonary arterial hypertension: a retrospective longitudinal cohort study. Pulmonary Circulation, 13(3), e12257. (doi: 10.1002/pul2.12257) (PMID:37404903) (PMCID:PMC10315452)
McGettrick, M., Dormand, H., Brewis, M., Johnson, M. K., Lang, N. N. and Church, A. C. (2022) Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease. Frontiers in Cardiovascular Medicine, 9, 1004169. (doi: 10.3389/fcvm.2022.1004169) (PMID:36582741) (PMCID:PMC9793745)
Stubbs, H., Brewis, M., Church, C. and Johnson, M. (2022) Towards telemedicine in pulmonary hypertension: assessing the feasibility of remote quality of life and exercise capacity assessment. Pulmonary Circulation, 12(4), e12144. (doi: 10.1002/pul2.12144) (PMID:36381292) (PMCID:PMC9647124)
Stubbs, H. , Lua, S., Brewis, M., Johnson, M. and Church, C. (2022) COMPERA 2.0 risk stratification in medically managed chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 60, 2200313. (doi: 10.1183/13993003.00313-2022) (PMID:35798358)
Stubbs, H., MacLellan, A., McGettrick, M., Jani, B. , Brewis, M., Church, C. and Johnson, M. (2022) Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland. Open Heart, 9(1), e002023. (doi: 10.1136/openhrt-2022-002023) (PMID:35477699) (PMCID:PMC9047890)
McGettrick, M., MacLellan, A., McCaughey, P., Bagot, C., Brewis, M.J., Lang, N.N. , Johnson, M.K. and Church, A.C. (2021) Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. BMJ Open, 11, e050281. (doi: 10.1136/bmjopen-2021-050281) (PMID:34462282)
Brash, L. et al. (2018) Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC: Basic to Translational Science, 3(2), pp. 176-186. (doi: 10.1016/j.jacbts.2018.01.013) (PMID:29876530) (PMCID:PMC5981010)
Stubbs, H., Lua, S., Ingram, J., Jani, B. D. , Brewis, M., Church, C. and Johnson, M. (2023) Remote exercise testing in pulmonary hypertension (PHRET). Pulmonary Circulation, 13(4), e12325. (doi: 10.1002/pul2.12325) (PMID:38148951) (PMCID:PMC10749888)
Arogundade, F., Jani, B. , Church, C., Brewis, M., Johnson, M. and Stubbs, H. (2023) The MRC Dyspnoea Scale and mortality risk prediction in pulmonary arterial hypertension: a retrospective longitudinal cohort study. Pulmonary Circulation, 13(3), e12257. (doi: 10.1002/pul2.12257) (PMID:37404903) (PMCID:PMC10315452)
McGettrick, M., Dormand, H., Brewis, M., Johnson, M. K., Lang, N. N. and Church, A. C. (2022) Cardiac geometry, as assessed by cardiac magnetic resonance, can differentiate subtypes of chronic thromboembolic pulmonary vascular disease. Frontiers in Cardiovascular Medicine, 9, 1004169. (doi: 10.3389/fcvm.2022.1004169) (PMID:36582741) (PMCID:PMC9793745)
Stubbs, H., Brewis, M., Church, C. and Johnson, M. (2022) Towards telemedicine in pulmonary hypertension: assessing the feasibility of remote quality of life and exercise capacity assessment. Pulmonary Circulation, 12(4), e12144. (doi: 10.1002/pul2.12144) (PMID:36381292) (PMCID:PMC9647124)
Stubbs, H. , Lua, S., Brewis, M., Johnson, M. and Church, C. (2022) COMPERA 2.0 risk stratification in medically managed chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 60, 2200313. (doi: 10.1183/13993003.00313-2022) (PMID:35798358)
Stubbs, H., MacLellan, A., McGettrick, M., Jani, B. , Brewis, M., Church, C. and Johnson, M. (2022) Predicting Group II pulmonary hypertension: diagnostic accuracy of the H2FPEF and OPTICS scores in Scotland. Open Heart, 9(1), e002023. (doi: 10.1136/openhrt-2022-002023) (PMID:35477699) (PMCID:PMC9047890)
McGettrick, M., MacLellan, A., McCaughey, P., Bagot, C., Brewis, M.J., Lang, N.N. , Johnson, M.K. and Church, A.C. (2021) Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. BMJ Open, 11, e050281. (doi: 10.1136/bmjopen-2021-050281) (PMID:34462282)
Brash, L. et al. (2018) Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension. JACC: Basic to Translational Science, 3(2), pp. 176-186. (doi: 10.1016/j.jacbts.2018.01.013) (PMID:29876530) (PMCID:PMC5981010)